Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study)
Open Access
- 13 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (12) , 3368-3371
Abstract
Tenofovir has been associated with a decrease in bone mineral density (BMD). However, data on changes in BMD after discontinuing tenofovir are lacking. We performed a two-centre randomized pilot study in virologically suppressed HIV-infected patients receiving tenofovir with osteopenia/osteoporosis (OsteoTDF study, ClinicalTrials.gov number NCT 01153217). Fifty-four patients were randomly assigned to switch from tenofovir to abacavir (n = 26) or to continue with tenofovir (n = 28). Changes in lumbar and total hip BMD were evaluated at Week 48 from baseline. Five patients discontinued the study (three from the tenofovir group and two from the abacavir group). No significant differences were detected between the groups at Week 48 (P = 0.229 for total hip and P = 0.312 for lumbar spine). However, hip BMD improved by 2.1% (95% CI −0.6 to 4.7) (P = 0.043) in the abacavir group and 0.7% (95% CI −0.9 to 2.4) (P = 0.372) in the tenofovir group. Lumbar spine BMD varied by −0.7% (95% CI −3.8 to 3.3) (P ≤ 0.001) in the abacavir group and −1.2% (95% CI −3.8 to 0.4) (P < 0.001) in the tenofovir group. Switching from tenofovir to abacavir led to a slight improvement in femoral BMD although no differences were detected between groups. Larger studies are necessary before firm recommendations can be made on the discontinuation of tenofovir in patients with a low BMD.Keywords
This publication has 16 references indexed in Scilit:
- HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort studyJournal of Bone and Mineral Research, 2013
- Fractures after antiretroviral initiationAIDS, 2012
- HIV: Inflammation and BoneCurrent HIV/AIDS Reports, 2011
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202The Journal of Infectious Diseases, 2011
- High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort studyAIDS, 2010
- Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral RegimenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Continuous antiretroviral therapy decreases bone mineral densityAIDS, 2009
- Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patientsAIDS, 2009
- The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected PatientsHIV Research & Clinical Practice, 2007
- Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS, 2006